These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 18972994)

  • 1. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994
    [No Abstract]   [Full Text] [Related]  

  • 2. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
    [No Abstract]   [Full Text] [Related]  

  • 3. 340B program presents opportunities--and challenges.
    Keough CL; Webster SA
    Healthc Financ Manage; 2009 Nov; 63(11):42-4, 46, 48. PubMed ID: 19891397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing 340B purchasing practices.
    Almeter PJ; Johnson GL; Saenz R
    Am J Health Syst Pharm; 2012 Aug; 69(16):1366-8, 1370-1. PubMed ID: 22855101
    [No Abstract]   [Full Text] [Related]  

  • 5. Notice regarding HRSA grant requirement--participation in the 340B drug pricing program--HRSA. Notice.
    Fed Regist; 1998 Oct; 63(204):56656-8. PubMed ID: 10187117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmaceuticals and medical devices: cost savings.
    ; Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403843
    [No Abstract]   [Full Text] [Related]  

  • 7. Notice regarding Section 602 of the Veterans Health Care Act of 1992; new drug pricing--PHS. Final notice.
    Fed Regist; 1995 Oct; 60(190):51488-9. PubMed ID: 10151188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmaceuticals and medical devices: cost savings. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
    [No Abstract]   [Full Text] [Related]  

  • 9. Tips for preparing for a 340B integrity audit.
    Wood W; Jorgenson J; Kelly W
    Healthc Financ Manage; 2012 Dec; 66(12):50-2. PubMed ID: 23252228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Health Policy Tracking Service, A Service of Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-21. PubMed ID: 21374837
    [No Abstract]   [Full Text] [Related]  

  • 11. Notice regarding section 602 of the Veterans Health Care Act of 1992 inclusion of outpatient hospital facilities--PHS. Notice.
    Fed Regist; 1994 Jun; 59(107):29300-1. PubMed ID: 10135125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fast track to 340B.
    Gricius RF; Wong D
    Healthc Financ Manage; 2016 Jan; 70(1):56-62. PubMed ID: 26863836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceuticals and medical devices: cost savings.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-32. PubMed ID: 24482891
    [No Abstract]   [Full Text] [Related]  

  • 14. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule; further delay of effective date.
    Health Resources and Services Administration, HHS
    Fed Regist; 2017 May; 82(96):22893-5. PubMed ID: 28574239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final notice regarding section 602 of the Veterans Health Care Act of 1992 entity guidelines--PHS. Final notice.
    Fed Regist; 1994 May; 59(92):25110-4. PubMed ID: 10134125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintaining qualification for 340B.
    Gricius RF; Wong D
    Healthc Financ Manage; 2016 Mar; 70(3):70-5. PubMed ID: 27183761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Who benefits from drug discounts? Drugmakers, hospitals battle over indigent-care program.
    Lee J
    Mod Healthc; 2013 Jul; 43(28):8-9. PubMed ID: 24044228
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmaceuticals and medical devices: cost savings. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-18. PubMed ID: 20213921
    [No Abstract]   [Full Text] [Related]  

  • 19. Medicaid program; cost limit for providers operated by units of government and provisions to ensure the integrity of federal-state financial partnership. Final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2007 May; 72(102):29747-836. PubMed ID: 17577965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicaid program; disproportionate share hospital payments. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2008 Dec; 73(245):77903-52. PubMed ID: 19143113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.